Skip to main content
Equibles

BOOTHBAY FUND MANAGEMENT, LLC

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 1549230 NEW YORK, NY
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$0
-$52,026 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$2,982,996
PutShares
202,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

BOOTHBAY FUND MANAGEMENT, LLC holds $666,641,771 across 159 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 465,787 $87,232,589
2 ABVX
Abivax S.A.
 563,367 $75,074,286
3 EXEL
Exelixis, Inc.
 804,095 $43,750,808
4 PCVX
Vaxcyte, Inc.
 534,163 $31,050,895
5 COGT
Cogent Biosciences, Inc.
 692,825 $26,812,327
6 CGEM
Cullinan Therapeutics, Inc.
 1,082,611 $19,714,346
7 TNGX
Tango Therapeutics, Inc.
 500,497 $15,645,536
8 AVTX
Avalo Therapeutics, Inc.
 702,051 $12,973,902

All Filings in SLS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,982,996 202,100
2025-12-31 $52,026 13,800